AKT1 and pulmonary hypertension: Thus treatment with Rac inhibitors remains a viable approach to suppress hypoxia-induced pulmonary hypertension, in particular if a combination of GEF inhibitors, or a single Rac inhibitor can be identified that would target Rac activation in PASMC as well as in innate immune cells.